<u>Review article</u>

VISUAL SIGNS AND SYMPTOMS OF CORTICOBASAL DEGENERATION

R.A. Armstrong D.Phil

Vision Sciences, Aston University, Birmingham B4 7ET, UK

<u>Corresponding Author</u>: R.A. Armstrong, Vision Sciences, Aston University, Birmingham B4 7ET, UK (Tel 0121-204-4102; Fax 0121-204-4048; EMail <u>R.A.Armstrong@aston.ac.uk</u>)

Abbreviated Title: Vision in corticobasal degeneration

Summary

Corticobasal degeneration is a rare, progressive neurodegenerative disease and a member of the 'parkinsonian' group of disorders which also includes Parkinson's disease, progressive supranuclear palsy, dementia with Lewy bodies, and multiple system atrophy. The most common initial symptom is limb clumsiness, usually affecting one side of the body, with or without accompanying rigidity or tremor. Subsequently, the disease affects gait and there is a slow progression to influence ipsilateral arms and legs. Apraxia and dementia are the most common cortical signs. Corticobasal degeneration can be difficult to distinguish from other parkinsonian syndromes, but if ocular signs and symptoms are present they may aid clinical diagnosis. Typical ocular features include increased latency of saccadic eye movements ipsilateral to the side exhibiting apraxia, impaired smooth pursuit movements, and visuo-spatial dysfunction especially involving spatial rather than object-based tasks. Less typical features include reduction in saccadic velocity, vertical gaze palsy, visual hallucinations, sleep disturbance, and an impaired electroretinogram. Aspects of primary vision such as visual acuity and colour vision are usually unaffected. Management of the condition to deal with problems of walking, movement, daily tasks, and speech problems is an important aspect of the disease.

Introduction

Corticobasal degeneration (CBD) is a rare, progressive neurodegenerative disease affecting approximately 4.9-7.3/100,000 of the population.[1] CBD largely affects individuals older than 60 years of age and death usually occurs within eight years of disease onset. The original description of the disease is based on three cases described as 'corticodentatonigral degeneration achromasia'.[2] The disorder has also been referred to as 'corticoganglionic degeneration'[3] but CBD remains the most popular descriptive term. Patients with a combination of clinical symptoms suggestive of the disorder are often referred to as having 'corticobasal syndrome' (CBS), while CBD is used strictly to describe cases verified at post-mortem.[4]

Clinical diagnosis of CBD can be difficult as symptoms are variable and often resemble those of other types of neurodegenerative disorder. First, CBD is classified as a subtype of frontotemporal lobar degeneration (FTLD)[5], the second most frequent form of cortical dementia of early-onset after Alzheimer's disease (AD).[6] Second, CBD is characterized by a cellular pathology consisting of abnormal cellular aggregations of the microtubule-associated protein (MAP) tau, and in this respect is similar to AD[7] and progressive supranuclear palsy (PSP).[8] Third, CBD is included within the 'parkinsonian' group of disorders, which includes Parkinson's disease (PD)[9], PSP[8], dementia with Lewy bodies (DLB)[10], and multiple system atrophy (MSA).[11]

Visual signs and symptoms are frequently present in parkinsonian syndromes.[8-11] CBD can be difficult to distinguish from the other parkinsonian syndromes, but if ocular signs and symptoms occur they can aid clinical diagnosis. Hence, this review describes: (1) the major clinical and pathological features of CBD, (2) the visual signs and symptoms that have been identified, (3) the visual features which may help to distinguish CBD from other parkinsonian disorders, and (4) management of the disease.

Clinical features

The onset of CBD is often sudden, patients exhibiting problems affecting cortical processing and motor function. The major clinical features include cortical signs such as apraxia and dementia[12], parkinsonism, palsy, and myoclonus.[13] The most common initial symptom is limb clumsiness affecting one side of the body, initially with or without accompanying rigidity or tremor.[12,14,15] Subsequently, the disease spreads to affect gait and there is a slow progression to influence ipsilateral arms and legs.[14]

The motor symptoms of CBD include parkinsonism, 'alien hand syndrome', and apraxia.[4] The parkinsonism usually affects the extremities of the limb, is frequently asymmetric, and characterized by rigidity and bradykinesia. Alien hand syndrome is present in approximately 60% of affected individuals and is a failure to control the movement of a hand accompanied by a sensation that the hand is 'foreign' to the patient.[16] The affected hand may also try to avoid specific external stimuli such as heat, cold, or touch and may exhibit an itching or prickling sensation. By contrast, the apraxia is characterized by an inability to repeat a specific movement of the hands and arms or an inability to carry out such a movement on command. 'Limb-kinetic' apraxia may also occur and is a dysfunction of fine movement control involving the hands.[16] Myoclonus has also been observed in CBD and may result from the degeneration of an enhanced 'long-loop reflex' pathway[17], rather than the classic 'cortical reflex' myoclonus pathway.[18]

Aphasia is present in some CBD patients and may involve disconnected speech and the omission of critical words.[1] As the disease progresses, the patient may lose the ability to speak completely. These problems may be accompanied by irritability, depression, and cortical dementia which can result in confusion with AD.[19] Neuropsychological problems may also be present and include deterioration of 'global' function, frontal lobe signs ('dysexecutive syndrome'), and learning difficulties.[20]

Neuropathology

Gross features

Neuropathologically, CBD is characterised by a progressive and asymmetric cortical atrophy affecting the anterior cerebral cortex[21], the fronto-parietal region[17], and the superior temporal cortex.[17] There is also atrophy of the basal ganglia, including the caudate nucleus[22] and substantia nigra.[23] Fig 1 illustrates a coronal section of the striatum and adjacent regions from a pathologically confirmed case of CBD showing enlarged lateral ventricles and atrophy of the caudate nucleus head, while the internal capsule, insula, putamen, and globus pallidus appear more normal. A summary of presenting features, motor symptoms, and brain regions affected in CBD compared with closely-related disorders such as PSP, PD, and AD is shown in Table 1.

Histopathology

There is a widespread neuronal and glial histopathology in CBD (Fig 2) affecting several different types of cell.[24] Abnormalities of neurons include enlarged neuronal cell bodies[25], thread-like dystrophic neurites[26], and abnormal cellular protein aggregates, viz., 'neuronal cytoplasmic inclusions' (NCI).[17] Pathology may also affect glial cells resulting in oligodendroglial inclusions[27] and degeneration of astrocytes and their processes ('astrocytic plaques').[28]

The typical distribution of the pathology in CBD is shown in Fig 3. First, pathology is frequently present in posterior frontal lobe anterior to the precentral gyrus but may be less severe in primary motor cortex.[21] Second, NCI are frequent in temporal lobe, including the superior temporal gyrus and parahippocampal gyrus, and in the cornu ammonis sectors of the hippocampus, less abundant in frontal and parietal cortex, and only present at low density in the dentate gyrus.[29] Third, NCI have been observed in association visual cortex (areas V2, V3).[30] Fourth, enlarged neurons occur in a variety of regions including frontal cortex[31], cingulate gyrus, superior frontal cortex, motor cortex, brainstem tegmentum, basal ganglia, thalamus, insula, claustrum, and amygdala.[27,31]

Molecular pathology

The pathology of CBD can be revealed using a variety of histological stains and

immunohistochemical procedures but the most sensitive are antibodies raised against the microtubule protein tau.[32] Tau is encoded by the tau gene on chromosome 17, alternative splicing of exons 2, 3, and 10 resulting in six possible isoforms. Hence, tau resulting from encoding exon 10 is known as 4-repeat (4R) tau while tau lacking exon 10 is referred as 3-repeat (3R) tau.[33] CBD is characterized by 4R tau similar to that of PSP, and distinct from those tauopathies that consist largely of either 3R tau alone, such as Pick's disease, or a mixture of 3R and 4R tau as in AD.[34] Electron microscopy reveals that the tau-immunoreactive NCI are composed of paired helically-wound filaments, those of CBD being wider than in AD and with a longer periodicity.[35] Inclusions can also be found in oligodendrocytes in cortical white matter.[36] These inclusions are often immunoreactive to tau, ubiquitin, heat shock protein, and alpha-B-crystallin. Neuropil threads may also occur in the white matter of the spinal cord especially the anterior funiculus.[23] β-amyloid (Aβ) protein deposits have also been observed in some cases of CBD resembling those found in AD.[15,37]

Neuroimaging

Magnetic resonance imaging (MRI) studies reveal the typical asymmetric cortical atrophy of CBD affecting posterior parietal and frontal regions together with atrophy of the corpus callosum.[38] In addition, functional MRI (fMRI), utilizing a simple finger tapping task, has revealed lower levels of activity in parietal cortex, motor cortex, and supplementary motor cortex in CBD.[38] Hypoperfusion in posterior frontal cortex and parietal cortex as well as abnormalities in thalamus, temporal cortex, basal ganglia, and pontocerebellar fibres has also been demonstrated using single photon emission computed tomography (SPECT).[39] Consistent with post-mortem findings, fDOPA positron emission tomography (PET) reveals diminished dopamine uptake in the striatum. In addition, hypometabolism in the thalamus has been reported.[40] Regional cerebral blood flow (rCBF) PET studies indicate that the clinically affected hemisphere has significantly reduced flow in posterior frontal and parietal cortices as well as in the thalamus and basal ganglia, while temporal and occipital lobes are essentially normal.[22] In a particularly significant study, SPECT was used in association with mapping of anatomical areas to reveal hypoperfusion in visual areas V1 and V2 in CBD.[41]

6

Diagnosis

Clinical and pathological diagnosis of CBS/CBD can be difficult as there is no specific clinical phenotype characteristic of the disease[42] and the neuropathology of CBD overlaps with that of AD, other forms of FTLD[43], the parkinsonian syndromes, and tauopathies.[19] Diagnosis is further complicated by the presence of possible subtypes of CBD including those characterized by selective atrophy of: (1) fronto-parietal, (2) exclusively frontal, and (3) superior temporal regions.[17] Some neuropsychiatric features of CBD may be useful in diagnosis. Hence, CBD subjects are significantly better than those with AD on tests of immediate and delayed recall of verbal material while AD subjects are better on tests of praxis, finger tapping speed, and motor tasks generally.[44] In addition, CBD subjects exhibit a wide range of cognitive and behavioural deficits which include in executive function and memory with non-specific language and visual spatial deficits whereas PSP subjects show apathy and impulsivity as consistent features.[45] CBD is currently diagnosed using criteria recommended by the National Institute of Health (NIH) Office of Rare Diseases.[42] A specific clinical phenotype is not required as diverse clinical symptoms may be present. Pathological diagnosis is based on the presence of: (1) tau-immunoreactive NCI together with inclusions in oligodendrocytes, and the presence of astrocytic plaques, (2) NCI in the white and gray matter of cortical regions and striatum, and (3) neuronal loss in focal cortical areas and in the substantia nigra.

Causes

No specific cause of CBD has yet been established and few risk factors have been identified. Hence, the disease does not appear to be associated with stress, overwork, pregnancy, smoking, alcohol, diet, or social class. In addition, there is no evidence that it is caused by a virus or other infectious agent. Approximately 32% cases have a family history of the disease,[46] familial cases being equally distributed between those exhibiting a primarily parkinsonian-type syndrome and those with cortical dementia. Mutations affecting the alternate-spliced exon 10 or the 5' regulatory region of the tau gene can result in the typical tau-reactive inclusions characteristic of CBD.[47] In

addition, a rare mutation of the tau gene has been reported in a single case of CBD.[48] Research also suggests a possible association between CBD and mutations of the progranulin[49], and fused in sarcoma[50] genes, which have also been implicated in FTLD.[5]

Treatment

There are no medications that can prevent or slow the development of CBD but various treatments are used to control symptoms. Hence, the parkinsonism is treated with levodopa/carbidopa, and rigidity specifically with baclofen.[51] Levodopa/carbidopa are usually less effective in CBD than in PD, however, but there may be some short-term improvement in rigidity and muscle stiffness. Limb dystonia is treated with botulinum toxin and myclonus with clonazepam and levetiracetam.[52] Memantine, a N-methyl-D-aspartate antagonist, and originally designed to reduce abnormal brain activity in AD, may have a similar affect in CBD.[52] Nevertheless, effectiveness of this treatment is controversial and can result in side effects such as headache, dizziness, and shortness of breath. Visual side effects have been observed in association with Levodopa/carbidopa (mydriasis, miosis, blepharospasm, eyelid ptosis, diplopia, and reduced vision), baclofen (diplopia and visual hallucinations), levetiracetam (diplopia), and memantine (blurred vision, yellowing of eyes and skin).

Visual signs and symptoms

The major visual signs and symptoms described to date in CBD are summarized in Table 2. Caution is required in interpreting these data as: (1) vision has been studied less frequently in CBD than in other parkinsonian disorders[8-11], (2) studies rely on a clinical diagnosis of CBS which can be difficult[42], and (3) CBD is rare and therefore sample sizes in clinical studies often limited.

Primary vision

There are few data concerning changes in primary vision in CBD such as visual acuity. Nevertheless, patients with a parkinsonian syndrome often complain of poor

vision as the disease progresses, and such changes could be present in CBD.[8-11] Nevertheless, in CBD patients, in which difficulties involving visuospatial tasks or in reading ability have been reported, the patients denied that they had a significant visual loss.[53] Photophobia appears to be significantly less frequent in CBD than in PSP.[54]

Visual fields

There have been few studies to date of visual field defects in any parkinsonian syndrome.[8-11] However, in a single case of a lateralized cortical-subcortical dementia, CBD being the most likely diagnosis, there was left visual field inattention consistent with right hemisphere pathology.[55] In addition, in six patients exhibiting posterior cortical atrophy (PCA), one of whom was diagnosed as CBD, a homonymous hemanopia, an inability to perceive more than a single object at a time (simultanagnosia), 'Balint's syndrome', visual agnosia, facial recognition problems, and hemispatial neglect were present.[56] Hence, an isolateral homonymous hemianopia may be suggestive of a diagnosis of PCA and therefore, of possible CBD.[56] In addition, the highly lateralized pathology characteristic of CBD suggests that hemianopias could be more common in this disorder than in other parkinsonian syndromes.

Eyelids and associated structures

Apraxia of eyelid opening has been observed in CBD and results from defective coordination between the action of the orbicularis oculi and levator palpebrae muscles.[57] Eyelid reflexes are impaired in several parkinsonian syndromes, especially in PSP[8], and includes the 'acoustic blink reflex' and 'acoustic startle reflex', responses to a sudden and unexpected sound by a brief closing of the eye. In a single case diagnosed as severe CBD, the blink reflex was completely absent.[58] Blepharospasm is a common symptom in parkinsonian syndromes, especially in PSP and MSA, and is also present in CBD.[59,60] Prominent blepharospasm in untreated patients with parkinsonism may suggest CBD.[61]

Eye movement

One of the most consistent eye movement problems reported in CBD is an increase in saccadic latency, i.e., time from appearance of a target to the beginning of the saccadic response, as measured by electro-oculography (EOG).[62,63] In a study which included six CBD and three atypical CBD cases, increased latency was ipsilateral to the side exhibiting the most significant apraxia.[62] In addition, in a study of 10 CBD cases, increased latency was correlated with the degree of apraxia.[64] In more atypical cases of CBD, vertical saccades and an early slowing of horizontal saccades have been reported but there was no increase in latency or early square-wave jerks.[62] Vertical saccade paralysis has been rarely observed in PD and CBD but is present in the majority of patients with PSP.[64] By contrast, normal antisaccadic error rates (where eye movements are deliberately made in a direction opposite to the visual stimulus) have been recorded in CBD, a feature also demonstrated in PD[65], but error rates are often increased in PSP.[64] However, in a study of 15 cases of CBS, patients were impaired on antisaccadic tasks and were not able to spontaneously self-correct antisaccadic errors as well as controls.[66] In addition, in more complex 'mixed' tasks, an increase in prosaccade and antisaccade error rates was reported in CBD.[65]

In one of the largest visual studies of CBD to date, which involved 36 well-characterized patients, smooth pursuit movements were commonly affected, a significant number of patients presenting with 'jerky' smooth pursuit movements, and in a small number of these patients, the range of movement was also restricted.[14] Decreased gain of smooth pursuit movements has also been observed in CBD.[64] Square-wave jerks have been reported in CBD.[14,67,68] while abnormal optokinetic nystagmus also appears to be common.[53,69]

Vestibulo-ocular reflex (VOR)

The vestibulo-ocular reflex (VOR) is a reflex eye movement that stabilizes images on the retina during movements of the head. The 'gain' of the VOR is the ratio of the change in eye angle to head angle during a head turn. If the gain is impaired (ratio not equal to unity), head movements result in image motion on the retina and blurred

vision. The gain of the VOR in the dark may be cancelled by fixation. Both MSA and PSP patients show this cancellation compared with control cases and PD[70], a response which could be related to cerebellar dysfunction. However, in CBD, in which there is less cerebellar pathology, there is little evidence for an effect on VOR.

Electroencephalography (EEG)

A slowing of general background activity and the appearance of focal slow waves have been recorded in CBD.[71] Intermittent delta activity has also been recorded in both CBD and PSP, but focal slow waves appear to be characteristic only of CBD.[71]

Evoked potentials (EP)

Increased latency of the N200 and P300 components of the auditory evoked potential (AEP) and the N13 and N20 components of the somatosensory evoked potential (SEP)[72] have been observed in CBD but there are no data on the corresponding visual evoked potential (VEP). However, there have been a number of studies of event-related potentials in CBD, which elicit the 'P300' evoked response, believed to reflect orientation, attention, stimulus evaluation, and memory. These evoked responses may be associated with neural activity in the temporal lobe, prefrontal lobe, limbic system, and thalamus.[73] Hence, in a study of the P300 event-related evoked response in patients with CBD using a visual stimulus[73], the latency of the P300 was increased and mean reaction times were greater in CBD and in PSP than PD, the degree of the response being correlated with the extent of motor disability.[73] 'Giant' cortical evoked potentials of high amplitude, recorded in a diverse range of conditions of myoclonic or cortical origin, have also been reported in CBD.[74]

Complex visual functions

In a case of typical PCA but presenting as 'atypical CBD', the patient exhibited a decline in spatial orientation and visual function which included fixation, optic ataxia, agraphia, acalculia, ideomotor apraxia, but with preserved colour matching.[75] CBD patients may also exhibit difficulties in locating objects within a visual space.[53]

Hence, visuo-spatial dysfunction in CBD appears to be greater when it involves spatial rather than object-based tasks.[76] These impairments could be related to pathological changes affecting the frontal lobe[77] and visual association areas[78], the latter suggesting that CBD should also be considered as a possible diagnosis in the presence of PCA.

Sleep disorders

Sleep disorders, which include excessive daytime sleeping, have been recorded in parkinsonian syndromes[79] and are often caused by pathology affecting the regulation of the sleep/awake transitional period and respiratory function. Sleep behavioural disorder episodes often decrease in frequency but sleep becomes increasingly abnormal as disease develops.[80] 'Idiopathic rapid eye movement' (iREM) sleep behaviour disorder has been observed in some parkinsonian syndromes, characterized by abnormal behaviour during sleep accompanied by iREM, probably resulting from neuronal loss in locus caeruleus and substantia nigra.[81] So common is iREM in association with parkinsonism, that it is often regarded as a strong indicator of the presence of a parkinsonian syndrome. However, iREM appears rare in CBD, recent estimates suggesting an incidence of only 5%, and its absence could be a useful additional diagnostic feature.[54]

Visual hallucinations

Visual hallucinations have been reported in several parkinsonian disorders especially in individuals with significantly impaired visual acuity, severe cognitive impairment[82], and Lewy body pathology. Hence, hallucinations occur most commonly in DLB and PD, but are less common in PSP and CBD.[54,83,84]

Differential diagnosis of CBD

A number of general features of the disease are suggestive of a diagnosis of CBD. First, degeneration in CBD affects both sensory and motor systems giving rise to a mixed 'perceptual-motor' syndrome, particularly characteristic of CBD.[85] Second,

brain atrophy in CBD is often lateralized.[86] Hence, in CBD, left side atrophy is usually greater than right side resulting in lateralized clinical signs, although bilateral atrophy can affect the superior parietal cortex (SPC) and striatum.[86] There are also differences in the pattern of brain atrophy in CBD and PSP, greater midbrain atrophy affecting midbrain, pons, thalamus, and striatum in PSP while, atrophy, of dorsal frontal and parietal cortex is greater in CBD.[86]

If visual signs and symptoms are present, they may provide additional support for a diagnosis of CBD. First, different combinations of oculomotor abnormalities are present in parkinsonian syndromes especially involving saccadic eye movement (Table 3). Hence, CBD is characterized by normal saccadic velocity but with abnormalities in saccadic gain which may distinguish CBD from PSP.[68] Second, vertical saccade paralysis in PSP is also likely to distinguish this disorder from CBD.[64] Nevertheless, clinicians should also be alert to intermediate and 'atypical' cases of CBD, in which vertical saccades may be present accompanied by an early slowing of horizontal saccades and the absence of square-wave jerks.[62] Third, although changes in saccadic latency are common to the majority of parkinsonian disorders, increased saccadic latency ipsilateral to the side exhibiting apraxia is more likely to indicate CBD.[62] However, saccadic eye movement dysfunction may be more similar in CBD, PD, and DLB, making these disorders more difficult to distinguish using these signs. Additional visual features that may aid a diagnosis of CBD are first, the presence of significant visuo-spatial dysfunction involving spatial rather than object-based tasks.[76] Second, sleep disorders and visual hallucinations, unrelated to medication, are rare in CBD compared with PD and DLB, and their presence can often exclude CBD as a possible diagnosis.

Management of the disease

CBD can affect many aspects of life and a multidisciplinary approach to management and care is often necessary. Management of CBD involves physiotherapy to maintain mobility and prevent contractures, gait-training to improve mobility and decrease the risk of falls, and the use of social workers and occupational therapists to oversee the provision of equipment and home adaptation. An important problem in the clinical

management of the disease is that many subjects with CBD exhibit problems in communication resulting in their inability to 'narrate a coherent story'.[87] This defect is likely to result from impaired information integration, related to the degree of frontal and parietal lobe atrophy, and clinicians should be aware of this problem in communicating with patients.

Visual deficits in parkinsonian-type syndromes are often important in influencing overall motor function. Visually, CBD can be regarded as an oculomotor apraxia accompanied by impairment of visuo-spatial processing and can be markedly debilitating.[53] Hence, identifying and correcting the visual problems as far as possible can significantly reduce the chances that a patient will suffer a serious fall and improve quality of life. Optometrists can work in collaboration with the patient and health care providers to identify and manage the specific visual deficits of the patient. First, although significant decline in visual acuity has not been specifically demonstrated in CBD, it is typical of the parkinsonian syndromes in general[8-11] and should be investigated in any suspected case of CBD. Second, visual fields should be tested as the pathology is often lateralized which could result in a hemianopia.[55,56] Third, although photophobia is less likely[54] the external eye should be monitored as blepharospasm and possibly dry eye may be present, these features being an essentially treatable visual feature of parkinsonian syndromes.[59-61] Artificial tears can be used to help dry eyes while blepharospasm has been treated successfully with botulinum toxin A injected at the junction of the preseptal and pretarsal parts of the levator palpebrae and orbicularis oculi muscles.[57] Fourth, patients with difficulties in opening their eyelids may have 'lid crutches' fitted to spectacle frames that can hold the lids open. Fifth, CBD patients have a particular difficulty with saccadic eye movements and deficits in gaze control may influence 'stepping behaviour' which may increase the risk of trips or falls.[88] Balance training in combination with eye movement and visual awareness exercises have been shown to improve gaze control in PSP[89] and may also help in CBD. Hence, patients can be referred to physiotherapists or occupational therapists. Sixth, CBD patients may have difficult in locating objects in visual space[53,76] and strategies to improve object recognition in the home may be beneficial. In addition, to maximize visual acuity, cataract surgery, and appropriate refractive correction can improve motor outcomes and associated

therapies.

Additional methods of managing CBD include cognitive stimulation which, through various activities and exercises, may improve memory, problem-solving, and language capability while physiotherapy can be used to strengthen muscles and improve posture.[90] Dysphagia can be a problem in CBD and exercise may be employed to stimulate the nerves used to trigger the swallowing reflex. Dietary changes may be helpful which incorporate foods and liquids that are easier to swallow. Feeding tubes may be necessary in more severe cases especially where there is a risk of malnutrition and dehydration. In addition, general support and care are necessary as dystonia and immobility can lead to sores.[52]

Conclusions

CBD is a complex parkinsonian syndrome in which patients exhibit a variety of signs and symptoms affecting both sensory and motor function. The visual problems of CBD have been relatively little studied compared with the other parkinsonian syndromes[8-11] as the condition is rare and difficult to clinically diagnose.[42] The existing data suggest that the most important visual signs are increased latency of saccadic eye movements ipsilateral to the side exhibiting apraxia[62], impaired smooth pursuit movements[14], and visuo-spatial dysfunction especially involving spatial rather than object-based tasks[76], but with relatively preserved primary vision. If ocular signs and symptoms are present, then they may aid differential diagnosis. The optometrist can play an important role in managing the disease both in ensuring that visual problems are corrected as far as possible and in referring patients to relevant health professionals.

Conflict of interest statement

The author reports no conflicts of interest.

References

15

1. Mahapatra RK, Edwards MJ, Schott JM, Bhatia KP. Corticobasal degeneration. Lancet Neurology 2004; 3: 736-743.

2. Rebeiz JJ, Kolodny EH, Richardson EP. Corticodentaonigral degeneration withneuronal achromasia. Arch Neurol-Chicago 1968; 18, 20-33.

3. Mathuranath PS, Xuereb JH, Bak T, Hodges JR. Corticobasic ganglionic degeneration and/or frontotemporal degeneration? A report of two overlap cases and review of the literature. J Neurol Neurosur PS 2000; 68: 304-312.

4. Armstrong RA. Corticobasal degeneration. In: Diet and Nutrition in Dementia and Cognitive Decline. E CR Martin and VR Preedy, Elsevier Inc., pp 91-99.

5. Cairns NJ, Bigio EH, Mackenzie IRA, Neumann M, Lee VMY, Hatanpaa KJ, White CL, Schneider JA, Halliday G, Duyckaertes C, Lowe JS, Holm IE, Tolnay M, Okamoto K, Yokoo H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG, Trojanowski JQ, Mann DMA. Neuropathologic diagnostic and nosological criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007; 114: 5-22.

6. Tolnay M, Probst A. Frontotemporal lobar degeneration- tau as a pied piper? Neurogenetics 2002; 4: 63-75.

7. Armstrong RA, Kergoat H. Oculo-visual changes and clinical considerations affecting older patients with dementia. Opthalmic Physiol Opt 2015; 35: 352-376.

8. Armstrong RA. Visual signs and symptoms of progressive supranuclear palsy. Clin Exp Optom 2011a; 95: 150-160.

9. Armstrong RA. Visual signs and symptoms of Parkinson's disease. Clin Exp Optom 2008; 91: 129-138.

10. Armstrong RA. Visual signs and symptoms of dementia with Lewy bodies. Clin Exp Optom 2012; 94: 621-630.

11. Armstrong RA. Visual signs and symptoms of multiple system atrophy. Clin Exp Optom 2014; 97: 483-491.

12. Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, Poewe W, Jellinger K, Chandhuri KR, Dolhaberriague L, Pearce RKB. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosur PS 1998; 64: 184-189.

13. Ueno E. Clinical features of corticobasal degeneration. Neuropathology 1996; 16: 253-256.

14. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration: a clinical study of 36 cases. Brain 1994; 117, 1183-1196.

15. Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS. Corticobasal degeneration: Neuropathological and clinical heterogeneity. Neurology 1997; 48, 959-969.

16. Belfor N, Amici S, Boxer AL, Kramer JH, Gomo-Tempini ML et al. Clinical and neuropsychological degeneration syndrome. Neuroradiology 2006; 49: 905-912.

17. Ikeda K. Basic pathology of corticobasal degeneration. Neuropathology 1997; 17: 127-133.

18. Carella F, Ciano C, Panzica F, Scaioli V. Myoclonus in corticobasal degeneration. Movement Disorders 1997; 12: 598-603.

19. Armstrong RA, Lantos PL, Cairns NJ. Overlap between neurodegenerative disorders. Neuropathology 2005; 25: 111-124.

20. Pillon B, Blin J, Vidailhet M, Deweer B, Sirigu A, Dubois B, Agid Y. The neuropsychological pattern of corticobasal degeneration: Comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology 1995; 45: 1477-

1483.

21. Tsuchiya K, Ikeda K, Uchihara T, Oda T, Shimada H. Distribution of cerebral cortical lesions in corticobasal degeneration: a clinicopathological study of five autopsy cases in Japan. Acta Neuropathol 1997; 94: 416-424.

22. Markus HS, Lees AJ, Lennox G, Marsden CD, Costa DC. Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT: Comparison with Parkinson's disease and normal controls. Movement Disord 1995; 10: 179-187.

23. Kawasaki K, Iwanaga K, Wakabayashi K, Yamada M, Nagai H, Idezuka J, Homna Y, Ikuta F. Corticobasal degeneration with neither argyrophilic inclusions nor tau abnormalities: a new subgroup. Acta Neuropathol 1996; 91: 140-144.

24. Feany MB, Dickson DW. Widespread cytoskeletal pathology characterises corticobasal degeneration. Am J Pathol 1995; 146: 1388-1396.

25. Mori H, Oda M. Ballooned neurons in corticobasal degeneration and progressive supranuclear palsy. Neuropathology 1997; 7: 248-252.

26. Komori T, Arai N, Oda M, Nakayama H, Murayama S, Amano N, Shibata N, Kobayashi M, Sasaki S, Yagishita S. Morphologic differences in neuropil threads in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy: a morphometric study. Neurosci Lett 1997; 233: 89-92.

27. Matsumoto S, Udaka F, Kameyama M, Kusaka H, Itoh H, Imai T. Subcortical neurofibrillary tangles, neuropil threads and argentophilic glial inclusions in corticobasal degeneration. Clin Neuropathol 1996; 15: 209-214.

28. Dickson DW, Feany MB, Yen SH, Mattiace LA, Davies P. Cytoskeletal pathology in non-Alzheimer degenerative dementia: new lesions in diffuse Lewy body disease, Pick's disease and corticobasal degeneration. J Neural Transm 1996; 47: 31-46.

29. Armstrong RA, Cairns NJ, Lantos PL. A quantitative study of the pathological lesions in the neocortex and hippocampus of 12 patients with corticobasal degeneration. Exp Neurol 2000; 163: 348-356.

30. Pikkarainen M, Kauppinen T, Alafuzoff I. Hyperphosphorylated tau in the occipital cortex in aged non-demented subjects. J Neuropath Exp Neur 2009; 68: 653-660.

31. Halliday GM, Davies L, Mcritchie DA, Cartwright H, Pamphlett R, Morris JGL. Ubiquitin positive lesions in corticobasal degeneration. Acta Neuropathol 1995; 90: 68-75.

32. Arima K. Tubular profile of the Gallyas positive and tau positive argyrophilic threads in corticobasal degeneration: an electron microscope study. Neuropathology 1996; 16: 65-70.

33. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. TINS 2010; 33: 317-325.

34. Trojanowski JQ, Dickson D. Update on the neuropathological diagnosis of frontotemporal dementias J Neuropath Exp Neur 2001; 60: 1123-1126.

35. Ksiezak-Reding H, Tracz E, Yang LS, Dickson DW, Simon M, Walt JS. Ultrastructural instability of paired helical filaments from corticobasal degeneration as examined by scanning transmission electron microscopy. Am J Pathol 1996; 149: 639-651.

36. Richter-Landsberg C, Bauer NG. Tau-inclusion body formation in oligodendroglia: the role of stress proteins and proteasome inhibition. International J Dev Neurosci 2004; 22: 443-451.

37. Armstrong RA. Density and spatial pattern of β-amyloid (Aβ) deposits in

corticobasal degeneration. Folia Neuropathol 2011b; 49: 14-20.

38. Seritan AL, Mendez MF, Silverman DHS, Hurley RA, Taber KH. Functional imaging as a window to dementia: corticobasal degeneration. J Neuropsych Clin N 2004; 16: 393-399.

39. Koyama, M., Yagishita, A., Nakata, Y., Hayashui, M., Bandoh, M., and Mizutani, T. Imaging of corticobasal degeneration syndrome. Neuroradiology 2007; 49, 905-912.

40. Akdemir UO, Tokcaer AB, Karakus A, Kapuco LO. Brain F-18-FDG PET imaging in the differential diagnosis of parkinsonism. Clin Nucl Med 2014; 39: E220-E228.

41. Valotassiou V, Papatriantafyllou J, Sifakis N, Tzavara C, Tsougos I, Kapsalaki E, Hadjigeorgiou G, Georgoulias P. Perfusion SPECT studies with mapping of Brodmann areas in differentiating Alzheimer's disease from frontotemporal degeneration syndromes. Nucl Med Commun 2012; 33: 1267-1276.

42. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropath Exper Neur 2002; 61: 935-946.

43. Mathew R, Bak TH, Hodges JR. Screening for cognitive dysfunction in corticaobasal degeneration syndrome: Utility of Addenbrooke's cognitive examination. Dem Ger Cogn Disord 2011; 31: 254-258.

44. Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Neurology 1996; 46: 720-726.

45. Burrell JR, Hodges JR, Rowe JB. Cognition in corticobasal syndrome and progressive supranuclear palsy: A review. Move Disord 2014; 29: 684-693S.

46. Borroni B, Goldwurm S, Cerini C, Cosseddu M, Meucci N, Mariani C, Pezzoli G, Padovani A. Familial aggregation in progressive supranuclear palsy and corticobasal degeneration. Eur J Neurol 2011; 18: 195-197.

47. Reed LA, Wszolek ZK, Hutton M. Phenotypic correlations in FTDP-17. Neurobiol Aging 2001; 22: 89-107.

48. Kara E, Ling H, Pittman AM, Shaw K, de Silva R, Simone R, Holton JL, Warren JD, Rohrer JD, Xiromerisiou G, Lees A, Hardy J, Houlden H, Revesz T. The MAPT p.152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol Aging 33: 2012; Article number 2231.e7.

49. Dopper EGP, Seelaar H, Chiu WZ, de Koning I, van Minkelin R, Baker MC, Rozemuller AJM, Rademakers R, van Swieten JC. Symmetrical corticobasal syndrome caused by a novel c.314dup progranulin mutation. J Mole Neurosci 2011; 45: 354-358.

50. Nagayama S, Minato-Hashibam N, Nakatam M, Kaito M, Nakanishi M, Tanaka K, Arai M, Akiyama H, Matsui M. Novel FUS mutation in patients with sporadic amylotrophic laterat sclerosis and corticobasal degeneration. J Clin Neurol: Aust 2012; 19: 1738-1739.

51. Kompoliti K, Goetz CG, Boeve BF, Maraganore DM, Ahiskog JE, Marsden CD, Bhatia KP, Greene PE, Przedborski S, Seal EC, Burns RS, Hauser RA, Gauger LL, factor Sa, Molho ES, Riley DF. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol-Chicago 1998; 55: 957-961.

52. Armstrong MJ. Diagnosis and treatment of corticobasal degeneration. Curr Trt Opt Neurol 2014; 16: No 282

53. Rajagopal R, Bateman R, Van Stavern GP. Visual involvement in corticobasal

syndrome. J Neuro-ophthalmol 2012; 32: 338-340.

54. Cooper AD, Josephs KA. Photophobia, visual hallucinations, and REM sleep behaviour disorder in progressive supranuclear palsy and corticobasal degeneration: A prospective study. Parkinsonism Relat D 2009, 15: 59-61.

55. Rey GJ, Tomer R, Levin BE, Sanchez-ramos J, Bowen B, Bruce JH. Psychiatric symptoms, atypical dementia, and left visual-field inattention in corticobasal ganglionic degeneration. Movement Disord 1995; 10: 106-110.

56. Formaglio M, Krolek-Salmon P, Tillikete C, Bernard M, Croisile B, Vighetto A. homonymous hemianopia and posterior cortical atrophy. Rev Neurol 2009: 165: 256-262.

57. Piccione F, Mancini E, Tonin P, Bizzarini M. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehab 1997; 78: 525-529.

58. Sepe-Monti M, Giubilei F, Marchione F, Colosimo C. Apraxia of eyelid opening in a case of atypical corticobasal degeneration. J Neural Transm 2003; 110: 1145-1148.

59. Leon-Sarmiento FE, Bayona-Prieto J, Gomez J. Neurophysiology of blepharospasm and multiple system atrophy: clues to pathophysiology. Parkinsonism Relat D 2005; 11: 199-201.

60. Rana AO, Kabir A, Dogu O, Patel A, Khondker S. Prevalence of blepharospasm and apraxia of eye opening in patients with parkinsonism, cervical dystonia, and essential tremor. Eur Neurol 2012; 68: 318-321.

61. Tolosa E, Compta Y. Early and prominent blepharospasm in untreated patients with parkinsonism should raise suspicion of progressive supranuclear palsy, multiple system atrophy, or corticobasal degeneration. J Neurol 2005; 253: 7-13.

62.   Revaud-Pechoux   S,   VidailhetM,   Gallouedec   G,   Litvan   I,

Gaymard B, Pierrot-Deseilligny C. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000; 54: 1029-1032.

63. Pierrot-Deselligny C, Rivauld-Pechoux S. Contribution of oculomotor exploitation for the etiological diagnosis of parkinsonian syndromes. Rev Neurologique. 2003; 159: S75-S81.

64. Vidailhet M, Rivaud S, Guiderkhouja N, Pillon B, Bonnet AM, Gaymard B, Agid Y, Pierrot-Deseilligny C. Eye-movements in parkinsonian syndromes. Ann Neurol 1994; 35: 420-426.

65. Rivaud-Pechoux S, Vidailhet M, Brandel JP, Gaymard B. Mixing pro- and antisaccades in patients with parkinsonsian syndromes. Brain 2007; 130: 256-264.

66. Garbutt S, Matlin A, Hellmuth J, Schenk AK, Johnson JK, Rosen H, Dean D, Kramer J, Nauhaus J, Miller BL et al. Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease. Brain 2008; 131: 1268-1281.

67. Altiparmak UE, Eggenberger E, Coleman A, Condon K. The ratio of square wave jerk rates to blink rate distinguishes progressive supranuclear palsy from Parkinson's disease. J Neuro-ophthalmol 2006; 26: 257-259.

68. Anderson T, Luxon L, Quinn N, Daniel S, Marsden CD, Bronstein A. Oculomotor function in multiple system atrophy: clinical and laboratory features in 30 patients. Movement Disord 2008; 23: 977-984.

69. Shibasaki H, Tsuji S, Kuroiwa Y. Oculomotor abnormalities in Parkinson's disease. Arch Neurol-Chicago 1979; 36: 360-364.

70. Rascol O, Sabatini U, Fabre N, Senard JM Simonett-Amoreau M, Montastruc JL, Clanet M, Rascol A. Abnormal vestibulo-ocular cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease. Movement Disord 1995; 10: 163-170.

71. Tashiro K, Ogata K, Goto Y, Taniwaki T, Okayama A, Kira J, Iobimatsu S. EEG findings in early-stage corticobasal degeneration and progressive supranuclear palsy: A retrospective study and literature review. Clin Neurophys 2006; 117: 2236-2242.

72. Takeda M, Tachibana H, Okuda B, Kawabata K, Sugita M. Electrophysiological comparison between corticobasal degeneration and progressive supranuclear palsy. Clin Neurol Neurosur 1998; 100: 94-98.

73. Wang LH Kuroiwa Y, Kamitani T, Li M, Takahashi T, Suzuki Y, Shimamura M, Hasegawa O. Visual event-related potentials in progressive supranuclear palsy, corticobasal degeneration, striatonigral degeneration and Parkinsons's disease. J Neurol 2000; 247: 356-363.

74. Baez-Martin MM, Morales-Chacon L, Gomez-Fernandez L, Cabrera-Abreu I, Alvarez L, Araujo F. Giant evoked potentials. Rev Neurol 2001; 33: 1120-1125.

75. Jellinger KA, Grazer A, Petrovic K, Ropele S, Alpi G, Kapeller P, Strobel T, Schmidt R. Four-repeat tauopathy clinically presenting as posterior cortical atrophy: atypical corticobasal degeneration? Acta Neuropathol 2011; 121: 267-277.

76. Bak TH, Caine D, Nearn VC, Hodges JR. Visuospatial functions in atypical parkinsonian syndromes. J Neurol Neurosur PS 2006: 77: 454-456.

77. Graham NL, Bak T, Patterson K, Hodges JR. Language function and dysfunction in corticobasal degeneration. Neurology 2003: 61: 493-499.

78. Tang-Wei DF, Josephs KA, Boeve BF, Dickson DW, Parisi JE, Petersen RC. Pathologically confirmed corticobasal degeneration presenting with visuospatial dysfunction. Neurology 2003; 61: 1134-1135.

79. Oertel WH, Depboylu C, Krenzer M, Vadasz D, Ries V, Sixel-Doring F, Mayer G REM sleep behaviour disorder as a prodromal stage of alpha-synucleinopathies: Symptoms, epidemiology, pathophysiology, diagnosis and therapy. Nervenarzt 2014; 85, 19-25.

80. Vetrugno R, Alessandria M, D'Angelo R, Plazzi G, Provini F, Cortelli P,

Montagno P. Status dissociatus evolving from REM sleep behavioural disorder in multiple system atrohy. Sleep Med 2009; 10: 247-252.

81. Turner RS. Idiopathic rapid eye movement sleep behaviour disorder is a harbinger of dementia with Lewy bodies. J Geriatr Psych Neur 2002; 15: 195-199.

82. Chapman FM, Dickinson J, McKeith I & Ballard C. Association among visual associations, visual acuity, and specific eye pathologies in Alzheimer's disease: Treatment implications. Am J Psychol 1999; 156: 1983-1985.

83. Ebersbach G. Hallucinations and psychosis in Parkinson's disease: consequences for diagnosis and management. Nervenheilkunde 2008; 27: 709.

84. Bertran K, Williams DR. Visual hallucinations in the differential diagnosis of parkinsonism. J Neurol Neurosur PS 2012; 83: 448-452.

85. Caselli RJ. Visual syndromes as the presenting features of degenerative brain disease. Semin Neurol 2000; 20: 139-144.

86. Boxer AL, Geschwind MD, Belfor N, Gorno-Tempini ML, Schauer GF, Miller BL, Weiner MW, Rosen HJ. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol-Chicago 2008; 63: 81-86.

87. Gross RG, Ash S, McMillan CT, Gunwardena D, Powers C, Libon DJ, Moore P, Liang TW, Grossman M. Impaired communications integration contributes to communication difficulty in corticobasal syndrome, Cog Behav Neurol 2010; 23: 1-7.

88. Di Fabio RP, Zampieri C, Tuite P. Gaze control and foot kinematics during stair climbing: Characteristics leading to fall risk in progressive supranuclear palsy. Phys Ther 2008; 88: 240-250.

89. Zampieri C, Di Fabio RP. Improvement of gaze control after balance and eye movement training in patients with progressive supranuclear palsy: A quasi-

randomised controlled trial. Arch Phys Med Rehab 2009; 90: 263-270.

90. Witt K, Deuschi G, Bartsch T. Frontotemporal dementias. Nervenarzt 2013; 84: 20-32.

Table 1. Comparison of presenting features, motor signs and symptoms, and brain regions affected in corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), Alzheimer's disease (AD), and Parkinson's disease (PD)

<u>Disorder</u>

<u>Feature</u>	<u>CBD</u>	<u>PSP</u>	<u>AD</u>	<u>PD</u>
Presentation	Sudden onset Asymmetric limb clumsiness No rigidity or tremor	Variable Dystonic rigidity Speech problems Falls	Insidious onset Short-term memory problems	Insidious onset Impaired mobility Autonomic problems
Motor symptoms	Parkinsonism Alien hand syndrome Apraxia	Gait and balance affected Downward gaze dysfunction	Mild	Akinesia Rigidity Tremor
Brain regions affected	Asymmetric Frontal, parietal temporal cortex Basal ganglia	Greater midbrain atrophy Dorsal frontal and parietal cortex less affected	General cortical	Basal ganglia Later cortical

Table 2. Summary of visual signs and symptoms in corticobasal degeneration (CBD)

Ocular function	Change in CBD
Primary vision	Generally affected in parkinsonism syndromes[8-11] but few data specific to CBD[53] Photophobia less frequent than in PSP[54]
Visual fields	Hemianopia may be present due to lateralized pathology[55,56]
Eyelids	Apraxia of eyelid opening.[57] Blink reflex may be affected.[58] Blepharospasm often present[61]
Saccadic eye movements.	Increase in saccadic latency ipsilateral to side with ataxia[562,63] Early slowing of horizontal saccades in atypical case[62] Vertical saccade paralysis rare[64] Increasing error rate in complex tasks[64]
Smooth pursuit movements	'Jerky' smooth pursuit movements and restricted range of movement[14,64]
Square-wave jerks	Reported in CBD[66,68]
Nystagmus	Abnormal optokinetic nystagmus in a proportion of patients[53,69]
VOR	Normal in CBD[70]
EEG	Slowing of background activity and appearance of focal slow waves[71]
Evoked potentials	Abnormal auditory and somatosensory evoked potential[72] Presence of 'giant' potentials[74]

Event-related potentials	Abnormal P300 using visual stimuli[72]
Complex visual dysfunction	Difficulty in locating objects within visual space[53,76-78]
Sleep disorder	Rare but iREM in approx. 5% of patients[54]
Visual hallucinations	Rare unrelated to medication[54,82-84]

Abbreviations: EEG = Electroencephalogram, iREM = Idiopathic rapid eye movement sleep disorder, PSP = Progressive supranuclear palsy, VEP = Visual evoked responses, VOR = Vestibulo-ocular reflex

Table 3. Comparison of saccadic eye movement parameters in corticobasal degeneration (CBD) with other parkinsonian syndromes (PD = Parkinson's disease, PSP = Progressive supranuclear palsy (PSP), DLB = Dementia with Lewy bodies, MSA = multiple system atrophy (MSA) (? = Limited data)

<div align="center">Syndrome</div>

Saccadic Parameter	CBD	PSP	PD	DLB	MSA
Velocity	-	+	-	-	-
Latency	+	+	+	+	-
Gain	+	+	+	+	?
Vertical saccadic paralysis	-	+	-	-	-
Anti-saccade error rate	-	+	+	+	?
Complex saccadic tasks	+	?	+	+	?

Titles to Figures

Fig 1. Coronal section of the striatum of the brain from a pathologically confirmed case of corticobasal degeneration (CBD). The figure shows enlarged lateral ventricles (LV), atrophy of the head of the caudate nucleus (CN), but more normal internal capsule (IC), external capsule (EC), claustrum (Cl), and putamen (PuT)

Fig 2. Tau-immunoreactive pathology in the superior frontal cortex of a case of corticobasal degeneration (CBD) showing features used in pathological diagnosis. Arrowheads = Neuronal cytoplasmic inclusions (NCI), Arrow = Astrocytic plaque, star = Dystrophic neurite (tau immunohistochemistry, antibody AT8; haematoxylin)

Fig 3. The areas of the brain likely to be affected by the pathology of corticobasal degeneration (CBD) (shown in bold in large font) (A = Amygdala, CG = Cingulate gyrus, CN = Caudate nucleus, GP = Globus pallidus, HC = Hippocampus, MC = Motor cortex, P = Pons, PC = Parietal cortex, PHG = Parahippocampal gyrus, Pu = Putamen, SFC = Superior frontal cortex, SN = Substantia nigra, STG = Superior temporal gyrus, Th = thalamus, VT = Ventral tegmentum. Other areas less likely to be affected in CBD (in normal text and small font) (CB = Cerebellum, DG = Dentate gyrus, Hy = Hypothalamus, IC = Inferior colliculus, ION = Inferior olivary nucleus, LC = Locus careuleus, MB = Mamillary bodies, OB = Olfactory bulb, OC = Occipital cortex, PAG = Periaqueductal gray, PT = Pontine tegmentum, RH = Raphe nuclei, RF = Reticular formation, RN = Red nucleus, S = Septum, SC = spinal cord, STN = Subthalamic nucleus, SuC = Superior colliculus) superimposed on a two-dimensional model of the brain based on that of WJH Nauta and M Feirtag (1986) *Fundamental Neuroanatomy*. WH Freeman & Co. Hence the cerebral cortex is represented at the right of the diagram with the striatum and thalamus below. Midbrain and brain stem nuclei are at the left of the diagram